AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 125552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (Vermox)
Number of subjects: 0
Study 31233255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (average dose of 7.2µg per day)
Number of subjects: 20
Study 31233255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (test phase)
Number of subjects: 20
Study 31233255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (long-term follow-up)
Number of subjects: 20
Study 27914822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate 16 g/m2 intravenously 6 hours after each cisplatin dose
Number of subjects: 125
Study 27914822 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 125
Study 27914822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Number of subjects: 125
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with at least one CVD risk factor
Number of subjects: 4019
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with two or more CVD risk factors
Number of subjects: 4019
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 4019
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4019
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4019
Study 25711323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of at least one risk factor by region
Number of subjects: 4019
Study 22880056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group training for UPS
Number of subjects: 162
Study 20032496 — intervention group
Group type: EXPERIMENTAL
Intervention: (SC)GOS/(LC)FOS/AOS (1.5 g . kg(‐1) . d(‐1))
Number of subjects: 113
Study 20032496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study 18824757 — intervention group
Group type: EXPERIMENTAL
Intervention: BITA in situ grafting
Number of subjects: 481
Study 18824757 — intervention group
Group type: COMPARATOR
Intervention: BITA Y configuration
Number of subjects: 481
Study 15819987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (DTI) analysis
Number of subjects: 45
Study 15819987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IVC + and IVR < 1
Number of subjects: 45
Study 15819987 — intervention group
Group type: COMPARATOR
Intervention: Controls (no intervention)
Number of subjects: 45
Study 11835452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (synthetic cannabinoid receptor agonist)
Number of subjects: 0
Study 11835452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10078893 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic floor muscle training
Number of subjects: 105
Study 10078893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 8625134 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 11
Study 8625134 — intervention group
Group type: COMPARATOR
Intervention: Control (no GM‐CSF)
Number of subjects: 11
Study 2301717 — intervention group
Group type: COMPARATOR
Intervention: Systemic clindamycin preoperatively
Number of subjects: 246
Study 2301717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined systemic clindamycin and topical ampicillin
Number of subjects: 246
Study 7470203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of cholestyramine twice daily
Number of subjects: 16
Study 7470203 — intervention group
Group type: COMPARATOR
Intervention: 8 g of cholestyramine twice daily
Number of subjects: 16
Study 7470203 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g of cholestyramine daily
Number of subjects: 16
Study 7470203 — intervention group
Group type: COMPARATOR
Intervention: 8 g of cholestyramine daily
Number of subjects: 16
Study 31331550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterokind (Chamomilla D6, Cina D6, Colocynthis D6, Lac defloratum D6, Magnesium chloratum D6)
Number of subjects: 125
Study 31331550 — intervention group
Group type: COMPARATOR
Intervention: Simethicone
Number of subjects: 125
Study 31331550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterokind
Number of subjects: 125
Study 28426903 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Btx‐A) - 50 units in 2.5 ml sterile saline
Number of subjects: 40
Study 28426903 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (placebo) - 2.5 ml
Number of subjects: 40
Study 28426903 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Btx‐A)
Number of subjects: 40
Study 25616206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Mg sulphate 40 mg kg(‐1) followed by an infusion of 10 mg kg(‐1) h(‐1)
Number of subjects: 40
Study 25616206 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 40
Study 23348071 — intervention group
Group type: COMPARATOR
Intervention: First quartile of fruit intake (23 g/day)
Number of subjects: 978
Study 23348071 — intervention group
Group type: EXPERIMENTAL
Intervention: Second quartile of fruit intake (mean intake not specified)
Number of subjects: 978
Study 23348071 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of fruit intake (mean intake not specified)
Number of subjects: 978
Study 23348071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of fruit intake (mean intake not specified)
Number of subjects: 978
Study 21550905 — intervention group
Group type: EXPERIMENTAL
Intervention: CoStar stent
Number of subjects: 303
Study 21550905 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 303
Study 19147457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 55 b.p.m.
Number of subjects: 12
Study 17530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant-behavioral therapy (OBT)
Number of subjects: 125
Study 17530683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 125
Study 17530683 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (AP)
Number of subjects: 125
Study 16490090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol formulated with long‐chain triglycerides (LCT)
Number of subjects: 90
Study 16490090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol formulated with mixed medium‐chain/long‐chain triglycerides (MCT/LCT)
Number of subjects: 90
Study 16490090 — intervention group
Group type: COMPARATOR
Intervention: Both propofol formulations (LCT and MCT/LCT)
Number of subjects: 90
Study 14658184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding 48 to 72 hours after total laryngectomy
Number of subjects: 42
Study 14658184 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding 10 to 12 days after total laryngectomy
Number of subjects: 42
Study 10650525 — intervention group
Group type: EXPERIMENTAL
Intervention: picasol (n-3 polyunsaturated fatty acids)
Number of subjects: 60
Study 10650525 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 8660109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine desensitisation
Number of subjects: 422
Study 8660109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 1984300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine CT
Number of subjects: 20
Study 1984300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT
Number of subjects: 20
Study 1984300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique (high-resolution CT for entire airway and cine CT at selected areas)
Number of subjects: 20
Study 6410450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (up to 600 mg)
Number of subjects: 0
Study 31591066 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard case definition combining acute respiratory symptoms and signs with ancillary tests
Number of subjects: 0
Study 31591066 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hospital-based pneumonia surveillance
Number of subjects: 0
Study 31591066 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up of children younger than 1 year
Number of subjects: 0
Study 28850681 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg dexamethasone every 8 hours for up to 4 days after surgery
Number of subjects: 0
Study 28850681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26619202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during haemodialysis (30-min bout)
Number of subjects: 15
Study 26619202 — intervention group
Group type: COMPARATOR
Intervention: Resting haemodialysis
Number of subjects: 15
Study 23871259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pressure therapy (OPT)
Number of subjects: 63
Study 23871259 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 63
Study 21537297 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 0
Study 21537297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofiber dressing
Number of subjects: 0
Study 20121985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise training (moderate intensity, 60-70% maximal oxygen uptake)
Number of subjects: 144
Study 20121985 — intervention group
Group type: COMPARATOR
Intervention: Flexibility and balance training (control group)
Number of subjects: 144
Study 20121985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise training
Number of subjects: 144
Study 20121985 — intervention group
Group type: COMPARATOR
Intervention: Flexibility and balance training
Number of subjects: 144
Study 16940094 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX) 2 g
Number of subjects: 221
Study 16940094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (CLI) 600 mg
Number of subjects: 221
Study 16940094 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg
Number of subjects: 221
Study 16940094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study 15302567 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg per day (40 mg twice daily)
Number of subjects: 0
Study 11753267 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort (300 mg, three times a day for 14 days)
Number of subjects: 16
Study 11753267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9266538 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation (90 mg/day)
Number of subjects: 25
Study 9266538 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 25
Study 9266538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8440431 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaldaride maleate 20 mg
Number of subjects: 176
Study 8440431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 3758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beclomethasone dipropionate suspension
Number of subjects: 14
Study 3758151 — intervention group
Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 14
Study 31473111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 g administered intravenously every 8 h for an average of 10.5 days
Number of subjects: 0
Study 31473111 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 0.5 g administered intravenously every 8 h for an average of 10.5 days
Number of subjects: 0
Study 31473111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Meropenem
Number of subjects: 0
Study 30274327 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 59
Study 30274327 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 59
Study 30274327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 28164344 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 22
Study 28164344 — intervention group
Group type: COMPARATOR
Intervention: Control (casual ice chewers)
Number of subjects: 22
Study 25466880 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood state
Number of subjects: 0
Study 25466880 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood state
Number of subjects: 0
Study 23098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 3344
Study 23098170 — intervention group
Group type: COMPARATOR
Intervention: Ingesting the entire daily dose of ≥1 hypertension medication at bedtime
Number of subjects: 3344
Study 23098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory BP thresholds for men
Number of subjects: 3344
Study 23098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory BP thresholds for women
Number of subjects: 3344
Study 23098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of ambulatory BP and CVD risk
Number of subjects: 3344
Study 23098170 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based reference thresholds for diagnosis of hypertension
Number of subjects: 3344
Study 21951244 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach to Goal intervention (multisession educational strategy)
Number of subjects: 0
Study 21951244 — intervention group
Group type: COMPARATOR
Intervention: Single-session brief educational intervention
Number of subjects: 0
Study 18440754 — intervention group
Group type: COMPARATOR
Intervention: bThrombin
Number of subjects: 164
Study 18440754 — intervention group
Group type: EXPERIMENTAL
Intervention: rThrombin
Number of subjects: 164
Study 16569109 — intervention group
Group type: EXPERIMENTAL
Intervention: Written expressive disclosure
Number of subjects: 60
Study 16569109 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit finding
Number of subjects: 60
Study 16569109 — intervention group
Group type: COMPARATOR
Intervention: Fact-control condition
Number of subjects: 60
Study 12654443 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 120
Study 12654443 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 120
Study 12654443 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only (no radiotherapy)
Number of subjects: 120
Study 14532316 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15 to 20 mg/wk)
Number of subjects: 67
Study 14532316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.75 mg qid
Number of subjects: 0
Study 10506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg orally every day
Number of subjects: 0
Study 10506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone 10 mg orally bid
Number of subjects: 0
Study 10506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0
Study 8522683 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrictive pericarditis
Number of subjects: 30
Study 8522683 — intervention group
Group type: COMPARATOR
Intervention: Restrictive cardiomyopathy
Number of subjects: 30
Study 8522683 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 30
Study 1365469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 42
Study 1365469 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 42
Study 6828614 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Number of subjects: 41
Study 6828614 — intervention group
Group type: COMPARATOR
Intervention: Non‐incentive Control
Number of subjects: 41
Study 28742685 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiation and surgery
Number of subjects: 82
Study 28742685 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiation and surgery with cetuximab
Number of subjects: 82
Study 28742685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cetuximab)
Number of subjects: 82
Study 29283254 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of electron-donating groups
Number of subjects: 0
Study 29283254 — intervention group
Group type: EXPERIMENTAL
Intervention: Steric effects
Number of subjects: 0
Study 26509382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CO inhalation (1.2 mL·kg(‐1) body mass)
Number of subjects: 9
Study 26509382 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 9
Study 26509382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CO inhalation
Number of subjects: 9
Study 24713188 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant Factor VIIa (rFVIIa)
Number of subjects: 497
Study 24713188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 497
Study 22731245 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin and rutin (2 tablets per day)
Number of subjects: 97
Study 22731245 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal topical therapy only)
Number of subjects: 97
Study 20668826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine 1.5 mg (perianal)
Number of subjects: 78
Study 20668826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine 6 mg (saddle)
Number of subjects: 78
Study 16822563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg daily for 6 months)
Number of subjects: 80
Study 16822563 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg daily for 6 months)
Number of subjects: 80
Study 16249527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet for 6 weeks
Number of subjects: 42
Study 16249527 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fat diet for 6 weeks
Number of subjects: 42
Study 16249527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet for 14 weeks (n=13)
Number of subjects: 42
Study 16249527 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fat diet for 6 weeks (after 14 weeks of high-carb)
Number of subjects: 42
Study 16249527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat diet for 14 weeks (n=8)
Number of subjects: 42
Study 16249527 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet for 6 weeks (after 14 weeks of high-mono)
Number of subjects: 42
Study 11878059 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenical (orlistat) 360 mg/day with diet
Number of subjects: 30
Study 11878059 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 30
Study 9536565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 184
Study 9536565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 12.5 mg
Number of subjects: 184
Study 9536565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 9536565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (both doses)
Number of subjects: 184
Study 7633301 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of apomorphine (0.005 mg/kg) in heroin addicts
Number of subjects: 2
Study 7633301 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of apomorphine (0.005 mg/kg) in healthy volunteers
Number of subjects: 2
Study 2673693 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (300 mg/day)
Number of subjects: 15
Study 2673693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 363236 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (20 g)
Number of subjects: 116
Study 363236 — intervention group
Group type: EXPERIMENTAL
Intervention: Naudicelle (linoleic acid with gamma-linolenic acid)
Number of subjects: 116
Study 363236 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (as a spread)
Number of subjects: 116
Study 363236 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (in capsules)
Number of subjects: 116
Study 29601904 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) incubation without prior curettage (‐Cur)
Number of subjects: 14
Study 29601904 — intervention group
Group type: COMPARATOR
Intervention: Methyl aminolevulinate (MAL) incubation after curettage (+Cur)
Number of subjects: 14
Study 28177953 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 40 mg/day
Number of subjects: 79
Study 28177953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 79
Study 26368268 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner wire
Number of subjects: 46
Study 26368268 — intervention group
Group type: COMPARATOR
Intervention: Nerve root retractor
Number of subjects: 46
Study 23764721 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized T1-MPRAGE sequence
Number of subjects: 40
Study 23764721 — intervention group
Group type: COMPARATOR
Intervention: Standard STIR sequence
Number of subjects: 40
Study 21561703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant posterior intravaginal slingplasty (IVS)
Number of subjects: 22
Study 21561703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant sacrospinous ligament fixation (SSLF)
Number of subjects: 22
Study 21561703 — intervention group
Group type: COMPARATOR
Intervention: Both IVS and SSLF
Number of subjects: 22
Study 18296554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 148
Study 16931673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BIS regimen (median BIS, 38.9)
Number of subjects: 74
Study 16931673 — intervention group
Group type: COMPARATOR
Intervention: Higher BIS regimen (mean BIS, 50.7)
Number of subjects: 74
Study 12947434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic glucose equivalent (GGE) doses of 10 and 20 GGE for yams, biscuits, white rice, and porridge; 24 and 48 GGE for 2-minute noodles
Number of subjects: 24
Study 12947434 — intervention group
Group type: EXPERIMENTAL
Intervention: GGE intake
Number of subjects: 24